5% and 15% Dextrose Prolotherapy Efficacy in Lateral Epicondylitis

Lateral Epicondylitis Clinical Trial

Official title:

Demonstration and Comparison of 5% Dextrose Prolotherapy and 15% Dextrose Prolotherapy Efficacy in Lateral Epicondylitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05066451
• Other study ID #: FTRTEZTASKIN
• Status: Completed
• Phase: N/A
• Start date: February 1, 2021
• Est. completion date: February 25, 2022

Study information

• Verified date: February 2022
• Source: Istanbul Physical Medicine Rehabilitation Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In the treatment of lateral epicondylitis, 5% dextrose prolotherapy is aimed to be more reliable than 15% prolotherapy in terms of side effects and to show that it is similar in terms of efficacy in treatment.

Description:

For this prospective randomized controlled study, volunteer patients who met the inclusion criteria and applied to the Health Sciences University, Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, Physical Medicine and Rehabilitation Outpatient Clinic will be included in the study. Participants who volunteered for the study will be divided into study groups and control groups by stratified randomization. A total of 26 volunteers will be recruited. A solution to be used for prolotherapy is containing 30% dextrose, 2% lidocaine, and physiological saline. In the beginning, all patients were asked about gender, age, body mass index, education level, occupation, duration of complaint, dominant side and affected extremity, previous treatments, and when the last treatment was applied. Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week. Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact. Patients in the control group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose, initially (0.) Week 3 and Week 6. The injection will be made with the same method as the study group. Measurements; will be evaluated at baseline (week 0), immediately after treatment at Week 3, Week 6, and Week 12. Patients; In the evaluation of the visual analog scale (VAS), quick Disabilities of the Arm, Shoulder and Hand (QDASH), Grip strength, hand dynamometer measurements, and adverse events during the study period will be noted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: February 25, 2022
• Est. primary completion date: February 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• Pain score =3 according to VAS for more than 3 months in the lateral elbow joint
• tenderness on palpation over the lateral epicondyle
• Positiveness in at least two of the tests specific to lateral epicondylitis(LE) (Mills test, resistant middle finger extension and cozen test),
• > 20 years old , < 60 years old

Exclusion Criteria:

• Patients who received physical therapy modalities and/or steroid injections in the last 3 months,
• Having a history of malignancy,
• Pregnant cases,
• Those who have bone and joint diseases in the neck, shoulder and elbow,
• Patients with infection in the treatment area,
• Patients with arrhythmia or pacemaker in the heart,
• Patients receiving coagulation disorder or anticoagulant therapy,
• Those with local dermatological problems,
• Patients with a history of surgery in the elbow joint,
• Having a tendon tear
• Presence of nerve involvement
• Lack of cooperation and refusal to participate in the study due to cognitive dysfunction

Related Conditions & MeSH terms

• Lateral Epicondylitis
• Tennis Elbow

Intervention

Other:
• %5 dextrose prolotherapy
Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 5% dextrose at the beginning(0.) 3rd week and 6th week. Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.
• %15 dextrose prolotherapy
Patients in the study group will receive a total of 3 sessions of prolotherapy solution containing 15% dextrose at the beginning(0.) 3rd week and 6th week. Prolotherapy was planned with the multiplanar injection technique (peppering technique) after palpating the most sensitive point on the lateral epicondyle and entering the lateral epicondyle from here and ensuring bone contact.

Locations

Country	Name	City	State
Turkey	Istanbul physical medicine rehabilitation training &research hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (4)

Fornalski S, Gupta R, Lee TQ. Anatomy and biomechanics of the elbow joint. Tech Hand Up Extrem Surg. 2003 Dec;7(4):168-78. — View Citation

Jensen KT, Rabago DP, Best TM, Patterson JJ, Vanderby R Jr. Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res. 2008 Jun;26(6):816-23. doi: 10.1002/jor.20600. — View Citation

Kahlenberg CA, Knesek M, Terry MA. New Developments in the Use of Biologics and Other Modalities in the Management of Lateral Epicondylitis. Biomed Res Int. 2015;2015:439309. doi: 10.1155/2015/439309. Epub 2015 May 31. Review. — View Citation

Rabago D, Slattengren A, Zgierska A. Prolotherapy in primary care practice. Prim Care. 2010 Mar;37(1):65-80. doi: 10.1016/j.pop.2009.09.013. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The upper extremity disability level	The upper extremity disability level will be evaluated by using the Quick Disabilities of Arm, Shoulder and Hand (QDASH) scale. The maximum score is 100 points. A higher score indicates a worse disability level.	Change from baseline upper extremity disability level at 3, 6, and 12 weeks
Primary	Pain intensity	Pain intensity will be evaluated by using a visual analog scale (VAS). The maximum score is 10 points. A higher score indicates a worse pain level.	Change from baseline pain intensity at 3, 6, and 12 weeks
Secondary	Hand grip strength	The standard evaluation tool (a hand dynamometer) will used for measuring grip and squeeze strength minimum value 0 and there is not maximum value, bigger values mean better outcome	Change from baseline hand grip strength at 3, 6, and 12 weeks